Profit Or Loss [Abstract]

Xbrane Biopharma - Filing #679209

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	238 729 SEK	—	57 618 SEK
Other income	—	13 707 SEK	—	20 914 SEK
Profit (loss) from operating activities	—	322 164 SEK	—	166 217 SEK
Finance income	—	2 407 SEK	—	− SEK
Finance costs	—	2 270 SEK	—	2 296 SEK
Profit (loss) before tax	—	322 028 SEK	—	168 513 SEK
Tax expense (income)	—	– SEK	—	– SEK
Profit (loss) from continuing operations	—	322 028 SEK	—	168 513 SEK
Profit (loss) from discontinued operations	—	66 144 SEK	—	4 001 SEK
Profit (loss)	388 172 SEK	388 172 SEK	172 513 SEK	172 513 SEK
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent	—	388 172 SEK	—	172 513 SEK
Profit (loss), attributable to non-controlling interests	—	– SEK	—	– SEK
Earnings per share [text block]	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations	—	1,122.00	—	659.00
Basic earnings (loss) per share	—	1,352.00	—	675.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations	—	1,122.00	—	659.00
Diluted earnings (loss) per share	—	1,352.00	—	675.00